Therapy Areas: Infectious Diseases
First Patient Dosed with Third ImmTAC Bispecific
9 December 2019 - - The first-in-human clinical trial of IMC-C103C, the third bispecific developed using UK-based T Cell Receptor biotechnology company Immunocore Ltd's ImmTAC technology platform, has launched, the company said.

IMC-C103C is focused on targeting tumours that express the protein MAGE-A4 (Melanoma-Associated Antigen A4) and is being developed in partnership with Genentech, a member of Switzerland's Roche Group (OTC: RHHBY).

The trial (IMC-C103C-101) is designed to study the safety and preliminary activity of IMC-C103C as a monotherapy and in combination with atezolizumab (Tecentriq) in patients with MAGE-A4-expressing cancers.

Immunocore, a leading T Cell Receptor biotechnology company, is focused on delivering first-in-class biological therapies that have the potential to transform the lives of people with serious diseases.

The company's primary therapeutic focus is oncology and it also has programs in infectious and autoimmune diseases.

Immunocore has a pipeline of proprietary and partnered programmes in development and the lead programme, tebentafusp (IMCgp100), has entered pivotal clinical studies as a treatment for patients with metastatic uveal melanoma.

Collaboration partners include Genentech, GlaxoSmithKline, AstraZeneca, Lilly, and the Bill and Melinda Gates Foundation. Immunocore is headquartered at Milton Park, Oxfordshire, UK, with offices in Conshohocken and Rockville, USA.

The company is privately held by a broad international investor base.